Fiercebiotech iconFiercebiotechSep 21, 2026

Novo struggles to appease restive investors with consumer plans, blockbuster ambitions

With reports leaking out of investor discontent, CEO Mike Doustdar opened Novo's Capital Markets Day by acknowledging that the company's leadership "have to convince" the audience that "there is a bright future for Novo."

Share this story

Send the public story page.

Useful takeaways from this story.

With reports leaking out of investor discontent, CEO Mike Doustdar opened Novo's Capital Markets Day by acknowledging that the company's leadership "have to convince" the audience that "there is a bright...

Building the complete brief

The page is ready to read now. The fuller skim-friendly version will appear here automatically.

The useful part

With reports leaking out of investor discontent, CEO Mike Doustdar opened Novo's Capital Markets Day by acknowledging that the company's leadership "have to convince" the audience that "there is a bright future for Novo."

Keep reading in the app

Open the app view to save this story, compare related coverage, and continue from the same source.

Open in app